Jett Steven, Boneu Camila, Zarate Camila, Carlton Caroline, Kodancha Vibha, Nerattini Matilde, Battista Michael, Pahlajani Silky, Williams Schantel, Dyke Jonathan P, Mosconi Lisa
Department of Neurology, Weill Cornell Medical College, New York, NY, United States.
Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Front Aging Neurosci. 2023 May 18;15:1183228. doi: 10.3389/fnagi.2023.1183228. eCollection 2023.
Many lines of evidence suggest that mitochondria have a central role in aging-related neurodegenerative diseases, such as Alzheimer's disease (AD). Mitochondrial dysfunction, cerebral energy dysmetabolism and oxidative damage increase with age, and are early event in AD pathophysiology and may precede amyloid beta (Aβ) plaques. probes of mitochondrial function and energy metabolism are therefore crucial to characterize the bioenergetic abnormalities underlying AD risk, and their relationship to pathophysiology and cognition. A majority of the research conducted in humans have used F-fluoro-deoxygluose (FDG) PET to image cerebral glucose metabolism (CMRglc), but key information regarding oxidative phosphorylation (OXPHOS), the process which generates 90% of the energy for the brain, cannot be assessed with this method. Thus, there is a crucial need for imaging tools to measure mitochondrial processes and OXPHOS in the human brain. Phosphorus-magnetic resonance spectroscopy (P-MRS) is a non-invasive method which allows for the measurement of OXPHOS-related high-energy phosphates (HEP), including phosphocreatine (PCr), adenosine triphosphate (ATP), and inorganic phosphate (Pi), in addition to potential of hydrogen (pH), as well as components of phospholipid metabolism, such as phosphomonoesters (PMEs) and phosphodiesters (PDEs). Herein, we provide a systematic review of the existing literature utilizing the P-MRS methodology during the normal aging process and in patients with mild cognitive impairment (MCI) and AD, with an additional focus on individuals at risk for AD. We discuss the strengths and limitations of the technique, in addition to considering future directions toward validating the use of P-MRS measures as biomarkers for the early detection of AD.
许多证据表明,线粒体在与衰老相关的神经退行性疾病(如阿尔茨海默病(AD))中起着核心作用。线粒体功能障碍、脑能量代谢异常和氧化损伤会随着年龄增长而增加,并且是AD病理生理学中的早期事件,可能先于β淀粉样蛋白(Aβ)斑块出现。因此,线粒体功能和能量代谢的检测对于表征AD风险背后的生物能量异常及其与病理生理学和认知的关系至关重要。大多数在人类中进行的研究都使用氟代脱氧葡萄糖(FDG)PET来成像脑葡萄糖代谢(CMRglc),但关于氧化磷酸化(OXPHOS)(为大脑产生90%能量的过程)的关键信息无法用这种方法评估。因此,迫切需要用于测量人类大脑中线粒体过程和OXPHOS的成像工具。磷磁共振波谱(P-MRS)是一种非侵入性方法,除了可以测量氢电位(pH)以及磷脂代谢的成分(如磷酸单酯(PMEs)和磷酸二酯(PDEs))外,还可以测量与OXPHOS相关的高能磷酸盐(HEP),包括磷酸肌酸(PCr)、三磷酸腺苷(ATP)和无机磷酸盐(Pi)。在此,我们对在正常衰老过程以及轻度认知障碍(MCI)和AD患者中使用P-MRS方法的现有文献进行了系统综述,特别关注有AD风险的个体。我们讨论了该技术的优点和局限性,此外还考虑了验证将P-MRS测量用作AD早期检测生物标志物的未来方向。